摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans-1-trifluoromethyl-4-methylcyclohexane | 13127-03-2

中文名称
——
中文别名
——
英文名称
trans-1-trifluoromethyl-4-methylcyclohexane
英文别名
trans-4-Methyl-trifluormethyl-cyclohexan;trans-1-Methyl-4-trifluormethyl-cyclohexan
trans-1-trifluoromethyl-4-methylcyclohexane化学式
CAS
13127-03-2
化学式
C8H13F3
mdl
——
分子量
166.186
InChiKey
YZKFCSOACWTUBF-LJGSYFOKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

反应信息

  • 作为产物:
    描述:
    1-trifluoromethyl-4-methylcyclohexan-1-ol 在 platinum(IV) oxide 吡啶4-二甲氨基吡啶氯化亚砜氢气 作用下, 以 四氢呋喃乙醚 为溶剂, 25.0~50.0 ℃ 、100.0 kPa 条件下, 反应 6.0h, 生成 trans-1-trifluoromethyl-4-methylcyclohexane
    参考文献:
    名称:
    在超声辐射下通过全氟烷基烯烃的氢化方便地合成氟化烷烃和环烷烃
    摘要:
    在室温下,在大气压下,在室温下,通过氢化位阻和电子贫乏的全氟烷基烯烃,合成几种1,4-二取代的环己烷。如果不使用超声波,无论使用何种催化剂和压力(1至120 bar),都难以实现加氢。超声辐射与金属催化的耦合极大地提高了全氟烷基烯烃的氢化效率。
    DOI:
    10.1016/j.jfluchem.2005.07.006
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2010137738A1
    公开(公告)日:2010-12-02
    The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
    本发明提供了一种新颖的杂环化合物。一种由通式(1)表示的杂环化合物,其中,R1和R2分别独立表示氢;苯基较低烷基基团,可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基;或环C3-C8烷基较低烷基基团;或类似物;R3表示较低炔基基团或类似物;R4表示可能具有从1,3,4-噁二唑基团(例如,卤素)或从吡啶基团等组成的取代基的苯基团;所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
  • [EN] 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS<br/>[FR] DÉRIVÉS DE 6 -AMINO- 2 - PHÉNYLAMINO- 1H-BENZIMIDAZOLE- 5 -CARBOXAMIDE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA PROSTAGLANDINE E2 SYNTHASE-1 MICROSOMALE
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2012076673A1
    公开(公告)日:2012-06-14
    This invention relates to compounds of formula (I) their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, L, M, W, R1, R2, R3, R4, R6, R7, R9, Ra, Rb have meanings given in the description.
    这项发明涉及式(I)的化合物,它们作为微粒体前列腺素E2合酶-1(mPGES-1)的抑制剂的用途,含有它们的药物组合物,以及它们作为治疗和/或预防炎症性疾病和相关症状的药物的用途。A、L、M、W、R1、R2、R3、R4、R6、R7、R9、Ra、Rb在描述中有给定的含义。
  • IL-17 Ligands And Uses Thereof
    申请人:DICE Molecules SV LLC.
    公开号:US20200247785A1
    公开(公告)日:2020-08-06
    Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.
    本文提供了新型配体及其药物组合物,可调节IL-17A。还提供了制备IL-17A调节剂的方法。这些化合物可能在治疗和/或预防炎症、癌症或自身免疫疾病等方面有用。
  • PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF
    申请人:Boyle Craig D.
    公开号:US20100190687A1
    公开(公告)日:2010-07-29
    The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 (“GPR119”) in a patient.
    本发明涉及嘧啶酮衍生物,包含嘧啶酮衍生物的组合物,以及使用嘧啶酮衍生物治疗或预防肥胖、糖尿病、代谢紊乱、心血管疾病或与G蛋白偶联受体119(“GPR119”)活性相关的疾病的方法。
  • HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS
    申请人:Takahashi Akira
    公开号:US20120065189A1
    公开(公告)日:2012-03-15
    The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R 1 and R 2 , each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R 3 represents a lower alkynyl group or the like; R 4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
    本发明提供了一种新型杂环化合物。所述杂环化合物的通式(1)表示,其中,R1和R2各自独立地表示氢;苯基低烷基,其可以在苯环上和/或低烷基上具有选自低烷基等的取代基;或环状C3-C8烷基低烷基;或类似物;R3表示低炔基或类似物;R4表示苯基,其可以具有选自1,3,4-噁二唑基(例如,卤素)或选自吡啶基等杂环基的取代基;所述杂环基可以具有至少一个选自低烷氧基等的取代基或其盐。
查看更多